Renal failure is a risk factor for cefepime-induced encephalopathy

Journal of Nephrology

Volumn 21, Issue 4, 2008, Pages 526-534

  Garcés, Erwin Otero ^a   e Azambuja, Mauro Francisco Andrade ^b   da Silva, Daiandy ^c   Bragatti, José Augusto ^a,c   Jacoby, Thalita ^a,c   Thomé, Fernando Saldanha ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Internal Medicine Service   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cefepime; Encephalopathy; Incidence; Neurotoxicity; Renal failure

Indexed keywords

CEFEPIME; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ACUTE KIDNEY FAILURE; BRAZIL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; FOLLOW UP; HOSPITALIZATION; METABOLIC ENCEPHALOPATHY; MIDDLE AGED; PROGNOSIS;

ANTI-BACTERIAL AGENTS; BRAIN DISEASES, METABOLIC; BRAZIL; CEPHALOSPORINS; ELECTROENCEPHALOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 52649138483     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis. 1996;23:454-461.
2. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of blood-stream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis. 1999;29:595-607.
3. Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med. 1996;100(suppl 6A):S68-S75.
4. Alpay H, Altun O, Biyikli NK. Cefepime-induced non-convulsive status epilepticus in a peritoneal dialysis patient. Pediatr Nephrol. 2004;19:445-447.
5. Bragatti JA, Rossato R, Ziomkowski S, Kliemann FAD. Encefalopatia Induzida por Cefepime: Achados clínicos e eletroencefalográficos em sete pacientes [article in Portuguese]. Arq Neuropsiquiatr. 2005;63:87-92.
6. Chandrasekhar J, Keller S, Scalon P. Cefepime induced encephalopathy. Chest. 2002;122:256S.
7. Chatellier D, Jourdain M, Mangalaboyi J, et al. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med. 2002;28:214-217.
8. Chetaille E, Harly L, de Cagny B, Gras-Champel V, Decocq G, Andrejak M. Crises convulsives associes a un surdosage en cefepime. Therapie. 1998;53:167-168.
9. Dixit S, Kurle P, Buyan-Dent L, Sheth RD. Status epilepticus associated with cefepime. Neurology. 2000;54:2153-2155.
10. Fishbain JT, Monaham TP, Canonico MM. Cerebral manifestations of cefepime toxicity in dialysis patient. Neurology. 2000;55:1756-1757.
11. Jallon P, Fankhauser L, Du-Pasquier R, et al. Severe but reversible encephalopathy associated with cefepime. Neurophysiol. 2000;30:383-386.
12. Maganti R, Jolin D, Rishi D, Biswas A. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav. 2006;8:312-314.
13. Martinez-Rodrigues JE, Barriga FJ, Santamaria J, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med. 2001;111:115-119.
14. Plensa E, Gallardo E, Ribera JM, Batlle M, Oriol A, Costa J. Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2004;33:119-120.
15. Wong KM, Chan WK, Chan YH, Li CS. Cefepime-related neurotoxicity in haemodialysis patient. Nephrol Dial Transplant. 1999;14:1756-1757.
16. Walker MC. Diagnosis and treatment of non-convulsive status epilepticus. CNS Drugs. 2004;15:931-939.
17. Dakdouki GK, Al-Awar GN. Cefepime-induced encephalopathy. Int J Infect Dis. 2004;8:59-61.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
19. Gill N, Nally VJ Jr, Fatica RA. Renal failure secondary to acute tubular necrosis: epidemiology, diagnosis, and management. Chest. 2005;128:2847-2863.
20. Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003;47:1853-1861.
21. Dosage of antimicrobial drugs in patients with renal impairment. In: Gilbert DN, Eliopoulos GM, Moellering RC, Sande MA, eds. The Sanford Guide to Antimicrobial Therapy. Hyde Park, VT (USA): Antimicrobial Therapy Inc; 2006:135.
22. Johnson H, Walter A. Intraventricular penicillin: a note of warning. JAMA. 1945;127:217-219.
23. Conway N, Beck E. Penicillin encephalopathy. Postgrad Med J. 1968;44:891-897.
24. Taylor R, Arze R, Gokal R, Stoddart JC. Cephaloridine encephalopathy. Br Med J (Clin Res Ed). 1981;283:409-410.
25. Sugimoto M, Uchida I, Mashimo T, et al. Evidence for involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology. 2003;45:304-314.
26. Primavera A, Cocito L, Audenino D. Nonconvulsive status epilepticus during cephalosporin therapy. Neuropsychobiology. 2004;49:218-222.
27. Kilion AD, Kallsen J, Cowl CT, Nauseef WM. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med. 1994;154:586-589.
28. Herishanu YO, Zlotnik M, Mostoslavsky M, Podgaietski M, Frisher S, Wirguin I. Cefuroxime-induced encephalopathy. Neurology. 1998;50:1873-1875.
29. Douglas MA, Quandt CM, Stanley DA. Ceftazidime-induced encephalopathy in a patient with renal impairment. Arch Neurol. 1988;45:936-937.
30. Chedrawai AK, Gharaybeh SI, Al-Ghwery SA, Al-Mohaimeed SA, Al-Shahwan SA. Cephalosporin-induced nonconvulsive status epilepticus in a uremic child. Pediatr Neurol. 2004;30:135-139.
31. Curtis DR, Game CJ, Johnston GA, McCulloch RM, MacLachlan RM. Convulsive action of penicillin. Brain Res. 1972;43:242-245.
32. Avoli M, Hwa G, Louvel J, Kurcewicz I, Pumain R, Lacaille JC. Functional and pharmacological properties of GABA-mediated inhibition in the human neocortex. Can J Physiol Pharmacol. 1997;75:526-534.
33. Niedermeyer E. Metabolic central nervous system disorders. In: Niedermeyer E, Lopes da Silva F, eds. Electroencephalography: Basic Principles, Clinical Applications, and Related Fields. Baltimore, MD (USA): Williams & Wilkins; 1994:416-431.
34. Handfourth A, Cheng JT, Manderkern MA, Treiman DM. Markedly increased mesiotemporal lobe metabolism in a case with PLEDs: further evidence that PLEDs are a manifestation of partial status epilepticus. Epilepsia. 1994;35:876-881.
35. Fountain NB, Waldman WA. Effects of benzodiazepines on triphasic waves: implications for nonconvulsive status epilepticus. J Clin Neurophysiol. 2001;18:345-352.
36. Treiman DM, Walton NY, Kendrick C. A progressive sequence of electrographic changes during generalized convulsive status epilepticus. Epilepsy Res. 1990;5:49-60.
37. Brenner RP. Is it status? Epilepsia. 2002;43:S103-S113.
38. Drislane FW. Presentation, evaluation, and treatment of nonconvulsive status epilepticus. Epilepsy Behav. 2000;1:301-314.
39. HCPA - Suprimentos - Farmácia - Sistema Gerencial [data file] [in Portuguese]. Porto Alegre (Brazil): Hospital de Clínicas de Porto Alegre; 2003.